Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.
In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd.